The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study

• Published in: Annals of internal medicine Vol. 152; no. 10; pp. 640 - 648
• Main Authors: PARKER, Benjamin D, SCHURGERS, Leon J, BRANDENBURG, Vincent M, CHRISTENSON, Robert H, VERMEER, Cees, KETTELER, Markus, SHLIPAK, Michael G, WHOOLEY, Mary A, IX, Joachim H
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American College of Physicians 18-05-2010
• Subjects: Aged; Aged, 80 and over; alpha-2-HS-Glycoprotein; Biological and medical sciences; Biomarkers - blood; Blood Proteins - metabolism; Calcium-Binding Proteins - blood; Cardiology. Vascular system; Cardiovascular disease; Coronary Disease - blood; Coronary Disease - mortality; Coronary heart disease; Epidemiology; Extracellular Matrix Proteins - blood; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors - blood; Follow-Up Studies; General aspects; Heart; Humans; Kaplan-Meier Estimate; Kidney diseases; Male; Matrix Gla Protein; Medical sciences; Middle Aged; Mortality; Proportional Hazards Models; Proteins; Public health. Hygiene; Public health. Hygiene-occupational medicine; Risk factors; Heart; Medicine; Fibroblast growth factor; Association; Matrix Gla protein; Mortality; Cardiovascular disease; Circulatory system; Coronary heart disease; Epidemiology
• ISSN: 0003-4819; 1539-3704
• DOI: 10.7326/0003-4819-152-10-201005180-00004

Fibroblast growth factor 23 (FGF23), uncarboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibitors of vascular calcification. Whether circulating levels of each are associated with cardiovascular disease (CVD) events or mortality in populations without end-stage renal disease is unknown.
To evaluate the associations of FGF23, ucMGP, and fetuin-A with mortality and CVD events.
Observational study.
12 outpatient clinics in the San Francisco Bay area.
833 outpatients with stable coronary artery disease (CAD), recruited from 11 September 2000 to 20 December 2002.
Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline. Participants were followed until 1 December 2008 for mortality and CVD events.
During a median follow-up of 6.0 years, 220 participants died and 182 had CVD events. Compared with participants with FGF-23 levels in the lowest tertile, those in the highest tertile had 2-fold greater risk for mortality (hazard ratio [HR], 2.15 [95% CI, 1.43 to 3.24]) and CVD events (HR, 1.83 [CI, 1.15 to 2.91]) after adjustment for traditional CVD risk factors, C-reactive protein levels, and kidney function. The highest ucMGP tertile was associated with lower mortality risk (HR, 0.48 [CI, 0.31 to 0.75]) and showed a nonsignificant trend toward lower CVD event risk by tertile analysis (HR, 0.65 [CI, 0.40 to 1.05])-an association that was significant when modeled continuously (P = 0.029). No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or CVD events (HR, 0.99 [CI, 0.64 to 1.55]) was observed.
Participants had prevalent CAD.
In outpatients with stable CAD, higher FGF23 and lower ucMGP levels are independently associated with mortality and CVD events.
American Heart Association.